MedTrace Logo

Low Dose Continuous Cyclophosphamide vs Standard Doxorubicin in Advanced Sarcoma Elderly Patients

NCT04656262 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 79

Last updated 2024-07-08

No results posted yet for this study

Summary

To compare the efficacy, as measured by time to treatment failure, of metronomic cyclophosphamide with respect to doxorubicin in elderly patients affected by mSTS.

Conditions

  • Soft Tissue Sarcoma Adult

Interventions

DRUG

Cyclophosphamide

Cyclophosphamide is formulated as coated tablets of 50mg for oral administration

DRUG

Doxorubicin

Doxorubicin is formulated as 60 mg/mq for infusional use (i.v use)

Sponsors & Collaborators

  • Ministry of Health, Italy

    collaborator OTHER_GOV

  • Istituto Oncologico Veneto IRCCS

    lead OTHER

Principal Investigators

  • Antonella Brunello · Istituto Oncologico Veneto

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-09-10
Primary Completion
2024-05-23
Completion
2024-05-23

Countries

  • Italy

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04656262 on ClinicalTrials.gov